Streetbeat News

Analyst Ratings

AMZN

Truist Securities has maintained a Buy rating on Amazon.com and raised its price target from $230 to $265, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:39 pm

APA

Truist Securities has maintained a Buy rating on APA Corporation but has lowered the price target from $46 to $34.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:36 pm

BF

Barclays analyst Lauren Lieberman has upgraded Brown-Forman (NYSE:BF) from Equal-Weight to Overweight and increased the price target from $43 to $53.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:36 pm

BNTC

JMP Securities has reiterated its Market Outperform rating for Benitec Biopharma (NASDAQ:BNTC) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:35 pm

PG

Barclays analyst Lauren Lieberman has downgraded Procter & Gamble (NYSE:PG) from Overweight to Equal-Weight, while maintaining the price target at $163.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:34 pm

AQST

JMP Securities has reiterated its Market Outperform rating for Aquestive Therapeutics, maintaining a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:32 pm

WLK

Barclays analyst Michael Leithead has upgraded Westlake (NYSE:WLK) from Equal-Weight to Overweight and increased the price target from $162 to $180.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:32 pm

ACN

AMTB

HES

ULCC

USB

Several top Wall Street analysts have upgraded their ratings for major companies, including Accenture, Hess Corporation, U.S. Bancorp, Frontier Group Holdings, and Amerant Bancorp. These upgrades reflect positive outlooks and increased price targets for these stocks.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 1:31 pm

EL

Piper Sandler has maintained an Overweight rating on Estee Lauder Cos and raised the price target from $114 to $122.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:30 pm

PROK

JP Morgan has initiated coverage on ProKidney with a Neutral rating, indicating a balanced outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:30 pm